We use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS permits sequencing of large genomic regions, high numbers of genes and/or high numbers of samples in a single efficient and cost-effective assay. In addition, NGS provides significantly higher sensitivity that traditional techniques, which permits the discovery of rare somatic mutations, many of which have been identified as important cancer drivers. With our somatic cancer panels we can detect mutations occurring even around 1% frequency reliably.

Additionally we provide the first functional test on tumour stem cells from the blood. The fluorescent cell balls carry beside EpCAM, the stem cell markers CD44 and ALDH 1 and low CD24. High numbers of spheroids are associated with metastases. The blood test detects cells washed out from the tumour into the blood. These cells are responsible for the metastatic spread and thus for the further course of disease. Cancer therapies aim to destroy these cells.

Moreover fluorescence in situ hybrydisation (FISH) test is available to detect translocations, inversions, deletions and duplications. During FISH test using a sample of the patient tissue special colour dyes are attached to specific parts of certain chromosomes in order to visualized and count them under fluorescence microscope. FISH testing is done i.e. on breast cancer tissue removed during biopsy to see if the cells have extra copies of the HER2 gene. The more copies of the HER2 gene that are present, the more HER2 receptors the cells have. These HER2 receptors receive signals that stimulate the growth of breast cancer cells.

Our core technology:

Our Onco-Treatment-Soft is a large and comprehensive source of constantly updated biomedical data. It integrates, synchronises, revises and expands reference data sources across all medical disciplines.

Onco-Treatment-Soft will help:

  • Identify treatments with potential benefit.
  • Avoid treatments with potential lack of benefit or safety risks.
  • Select options for clinical trials.